Pfizer competitive grant to develop a shared decision-making tool for ATTR-CM patients
Pfizer is offering a competitive research grant to fund development of a shared decision-making (SDM) decision aid for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) to improve understanding of disease trajectory, treatment options, and alignment of care with patient values. Applicants must submit a complete proposal through the Cybergrants portal (www.cybergrants.com/pfizer/Rese…
Overview
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a progressive, life-threatening condition associated with significant morbidity, mortality, and burden on patients, caregivers, and healthcare systems. The multisystemic disease course is often characterized by diagnostic delays, …
Funding Source
Awards & funding
Eligibility
I. Eligibility
Geographic Scope:
United States
Applicant Eligibility Criteria:
Medical societies or professional organizations, in partnership with patient advocacy organizations, that include transthyretin cardiac amyloidosis (ATTR-CM) as one of the focus areas are e…
Dates
Supporting links
Secure Grant Funding 10x Faster
Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.
Already have an account? Sign In
Trusted by 500+ Happy Customers